ClinicalTrials.gg
CompletedNCT00470678Updated Nov 18, 2016

EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

A Phase 3 interventional study of ranibizumab in Choroidal Neovascularization and Age-Related Macular Degeneration, sponsored by Novartis. Completed at 6 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2016-11-18.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
95
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 45 studies testing ranibizumab in Choroidal Neovascularization — none open to participants now, none under way, none of them phase 3. Ranibizumab · Choroidal Neovascularization.

Enrollment
19th of 45
95 · median 62
Started
2007
with 6 others
Phase 3
11 of 45
none open now
Registered
9th of 45
by date
Lead sponsor
5 of 45
Novartis

Among the 45 studies testing ranibizumab in Choroidal Neovascularization, this one is the 19th largest by enrollment, is one of 7 that started in 2007, is one of 11 in phase 3, and was the 9th registered.

Choroidal Neovascularization

214 studies on the registry are indexed under Choroidal Neovascularization; 12 are open to participants now.

Browse Choroidal Neovascularization studies →

Open to participants now

None of the 45 studies testing ranibizumab in Choroidal Neovascularization is open now. The open studies under Choroidal Neovascularization, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 6 Choroidal Neovascularization studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 45 studies testing ranibizumab in Choroidal Neovascularization as a file.
02

Study summary

This study will evaluate efficacy and safety for monthly ranibizumab 0.5 mg intravitreal injections in Asian patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.

03

Conditions studied

  • Choroidal Neovascularization
  • Age-Related Macular Degeneration

Keywords

  • Age-related
  • macular
  • degeneration
  • AMD
  • Ranibizumab
  • Anti-VEGF
  • choroidal
  • neovascularization
  • CNV
  • Asian patients
  • Korea
  • Taiwan
  • associated
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female Asian patients 50 years of age or greater.
  • Patients with primary or recurrent subfoveal CNV secondary to AMD, including those with predominantly classic, minimally classic or active occult lesions with no classic component.
  • Patients who have a BCVA score between 73 and 24 letters (approximately 20/40 to 20/320 Snellen equivalent), inclusively, in the study eye.
  • Total area of CNV (including both classic and occult components) encompassed within the lesion must be >= 50% of the total lesion area
  • Total lesion area must be \<= 12 disc areas

Exclusion criteria

Exclusion Criteria:

  • Patients who have in the fellow eye a Snellen equivalent below 20/200
  • Presence of angioid streaks, presumed ocular histoplasmosis syndrome, myopia (exceeding -8 diopters), or CNV secondary to causes other than AMD in the study eye
  • Subfoveal fibrosis or atrophy in the study eye
  • Total area of CNV (including both classic and occult components) encompassed within the lesion must be >= 50% of the total lesion area
  • Total lesion area must be \<= 12 disc areas
  • Vitreous hemorrhage, retinal tear or history of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the study eye.
  • Active, or history of, ocular inflammation or infection in the study eye within the last 30 days prior to screening.
  • Uncontrolled glaucoma in the study eye
  • Treatment in the study eye with verteporfin, external-beam radiation therapy, subfoveal focal laser photocoagulation, vitrectomy, submacular surgery, or transpupillary thermotherapy within 30 days prior to screening
  • Previous treatment with anti-angiogenic drugs (pegaptanib, ranibizumab, bevacizumab, anecortave acetate, , protein kinase C inhibitors, squalamine, siRNA, VEGF-Trap etc.) for neovascular AMD in the study eye. Treatment of the fellow eye is permitted if administered > 30 days before screening.
  • History of intraocular surgery in the study eye including pars plana vitrectomy, except for uncomplicated cataract surgery more than 60 days prior to screening
  • History of YAG laser posterior capsulotomy in the study eye within 30 days prior to screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    1

    Ranibizumab

    Drug: ranibizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Mean change in best-corrected visual acuity (BCVA) from Baseline, Month 4 and Month 12 as assessed with ETDRS (Early Treatment for Diabetic Retinopathy Study)-like charts at a distance of four meters

    Time frame: Baseline, Month 4 and Month 12

Secondary outcomes

  1. Changes in the retinal structure from baseline as assessed by fundus photography and fluorescein angiography, Month 4 and Month 12

    Time frame: Month 4 and Month 12

  2. Safety by rates of adverse events and serious adverse events, ophthalmic examinations, tonometry, and vital signs, baseline, Month 4, Month 6 and Month 12

    Time frame: Baseline, Month 4, Month 6 and Month 12

07

Study locations

6 sites
  • Novartis Investigative Site
    Daegu, Korea, Republic of
  • Novartis Investigative Site
    Pusan, Korea, Republic of
  • Novartis Investigative site
    Seoul, Korea, Republic of
  • Novartis Investigative Site
    Kaohsiung, Taiwan
  • Novartis Investigative Site
    LinKou, Taiwan
  • Novartis Investigative site
    Taipei, Taiwan
08

References and documents

Publications

  • Kwon OW, Lee FL, Chung H, Lai CC, Sheu SJ, Yoon YH; EXTEND III study group. EXTEND III: efficacy and safety of ranibizumab in South Korean and Taiwanese patients with subfoveal CNV secondary to AMD. Graefes Arch Clin Exp Ophthalmol. 2012 Oct;250(10):1467-76. doi: 10.1007/s00417-012-1970-3. Epub 2012 Mar 2. PubMed 22382503 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2007
First posted
May 8, 2007
Start
Jun 2007
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Last update
Nov 18, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00470678
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
May 8, 2007
Start date
Jun 2007
Primary completion
Nov 2008
Completion
Nov 2008
Last update
Nov 18, 2016

Study contacts

Novartis Pharma
study chair · Novartis
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion